Athersys, Inc. (Nasdaq:ATHX - News) announced its financial results for the fourth quarter and year 
ended December 31, 2011.
Fourth Quarter and Recent Highlights:
- Raised $9.0 million in March 2012 through a private placement of common stock and warrants;
- Announced positive results from Phase I clinical trial evaluating MultiStem(R) treatment for individuals undergoing allogeneic hematopoietic stem cell transplants (HSCTs) for the treatment of leukemia and related conditions and the risk for graft-versus-host disease;
- Awarded grant funding aggregating $3.6 million to advance development of MultiStem therapy for the treatment of traumatic brain injury and to further develop cell therapy formulations and manufacturing capabilities;
- Published in Circulation Research the results from a successful Phase I clinical study of MultiStem treatment of patients who had recently suffered an acute myocardial infarction;
- Granted a patent covering the use of non-embryonic multipotent stem cells for the treatment of cardiovascular conditions, capping a productive year for our stem cell patent prosecution;
- Secured up to $0.6 million in funding from Fast Forward, LLC to support development of MultiStem product to treat multiple sclerosis;
- Entered into a $20 million equity purchase agreement with Aspire Capital, of which $1.4 million has been received;
- Recorded revenues of $2.6 million and a net loss of $4.3 million for the fourth quarter ended December 31, 2011; and
- Ended the year with $12.8 million in cash, cash equivalents and available-for-sale securities.
ATHX Athersys reports Q4 EPS ($0.18) vs FactSet ($0.14).
